Nintedanib + pemetrexed/cisplatin in malignant pleural mesothelioma: Phase II biomarker data from the LUME-Meso study
Nowak K, Grosso F, Steele N, Novello S, Popat S, Greillier L, John T, Leighl N, Reck M, Pavlakis N, Sørensen J, Planchard D, Ceresoli G, Hughes B, Mazières J, Socinski M, Salnikov A, Kitzing T, Braunger J, Pietzko K, Scagliotti G
Learn more about the science behind this presentation in the papers and other materials below
Nintedanib is being investigated in malignant pleural mesothelioma (MPM) and is not approved for this use. The efficacy and safety of nintedanib in MPM have not been established.